Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) has submitted a New Drug Application (NDA) to the U.S. FDA for relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. This submission is supported by data from Phase 3 ROSELLA and earlier Phase 2 trials, which demonstrated improved progression-free and overall survival with a favorable safety profile. This marks CORT's second NDA under FDA review, signifying a key pipeline advancement and potential market expansion beyond its existing hypercortisolism indication.

Analysis

Corcept Therapeutics (CORT) has achieved a significant regulatory milestone by submitting a New Drug Application (NDA) to the U.S. FDA for relacorilant as a treatment for platinum-resistant ovarian cancer. The submission is underpinned by compelling data from the Phase 3 ROSELLA trial, which demonstrated that the drug, in combination with nab-paclitaxel, improved both progression-free and overall survival versus nab-paclitaxel alone. Critically, the combination therapy exhibited a favorable safety profile, not increasing the incidence or severity of adverse events, which is a key consideration for regulatory review and future clinical adoption. This marks the company's second NDA currently under FDA review, signaling a pivotal expansion of its late-stage pipeline beyond its established endocrinology focus into the competitive oncology market. Management's proactive preparation for a commercial launch indicates a high degree of confidence in the drug's prospects, positioning Corcept for a potentially rapid market entry upon approval. The modest 0.21% stock price increase suggests the market may be awaiting the FDA's final decision before fully pricing in the drug's commercial potential.

Key Decisions for Investors

• The NDA submission for relacorilant materially de-risks a key pipeline asset; investors should re-evaluate Corcept's valuation to account for the increased probability of a new revenue stream in oncology.
• Investors should closely monitor communications regarding the FDA's acceptance of the NDA and the subsequent announcement of a PDUFA target date, as this will be the next major catalyst for the stock.
• Given that Corcept now has two distinct late-stage assets under FDA review (oncology and hypercortisolism), its risk profile is becoming more diversified, which may warrant a higher valuation multiple if approvals are granted.
• The muted immediate stock reaction to this significant news could present a strategic entry point for those with a bullish outlook on relacorilant's approval and commercial prospects.